Amarin announced earlier that the number of patients enrolled in the company's REDUCE-IT cardiovascular outcomes study of Vascepa capsules has surpassed 6,000. The study is being conducted under Amarin's previously announced Special Protocol Assessment agreement with the FDA. Amarin said, ""Reaching the 6,000 patient mark in the REDUCE-IT trial represents significant progress toward full enrollment and another significant highlight for Amarin in 2013. The results of REDUCE-IT may enable us to seek additional indications for Vascepa including cardiovascular risk reduction, which would represent a patient population estimated to be almost twice that of the combined indications studied in the MARINE and ANCHOR trials or approximately 70 million adults in the United States alone."